Novartis Avidity Drug Fails Late-Stage Study Again

Novartis saw a treatment for a rare muscle-wasting disease fail a late-stage study, marking the third clinical-trial setback in a week, according to Bloomberg. The medicine was the centerpiece of Novartis’s $12 billion takeover of Avidity Biosciences and has raised questions about the drugmaker’s growth prospects.